News and Trends 29 Apr 2021 BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors …inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These promising results did more than… April 29, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
Infographics 19 Jan 2017 Infographic: A History of Approved Therapeutic Antibodies …With the recent advancements in antibody engineering, we can expect to see an improvement of their half-lives, effector functions or incorporation into antibody-drug conjugates. Since the first antibody hits the… January 19, 2017 - 1 minutemin - By Marie Godar Share WhatsApp Twitter Linkedin Email
In Depth 19 Jan 2022 Glycans Hit the Sweet Spot in Diagnostics …the glycosylation patterns of antibodies reveals much more insights into disease progression than just looking at antibody levels. For instance, while the levels of a type of antibody known as… January 19, 2022 - 5 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 OncoC4 and BioNTech partner in the commercialization of cancer drug candidate …ONC-392, which is an anti-CTLA-4 monoclonal antibody, is in phase 1/2 trial, following the U.S. Food and Drug Administration’s (FDA) nod for Fast Track designation for immunotherapy-resistant non-small cell lung… March 23, 2023 - 2 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Interview 29 Nov 2022 LAG-3: The next big checkpoint inhibitor target …is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of the antibody drug ipilimumab (Yervoy)… November 29, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2018 Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy …a fusion protein that combines engineered T cell proteins with antibody fragments. One end of the fusion protein binds with specific antigens on the surface of tumor cells, whereas the… November 20, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 3 Jul 2018 NASA Studies How Outer Space Affects the Immune System NASA is using an antibody assay to investigate the effect of space flight on white blood cells in astronauts on the International Space Station. The assay used by NASA measures… July 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2020 Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II …the market such as Humira and Cosentyx, these antibody drugs aren’t well suited to subcutaneous injections because they can’t penetrate subcutaneous tissue well. Affibody’s psoriasis candidate is a protein drug… June 22, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 May 2025 Nine biotech companies in Montreal to keep an eye on in 2025 …funding round in 2024 Situated in Montreal, Ability Biotherapeutics has come up with its discovery engine AbiLeap that combines AI and a database of antigen-antibody interactions in order to develop… May 13, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2019 Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis Founded in March this year, Alentis Therapeutics has bagged a Series A round of €11.1M (CHF 12.5M) to develop antibody drugs treating liver fibrosis, which currently has no approved treatments…. April 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2017 Swedish Oncology Biotech makes a Large IPO for its Peptides …Squibb and is the first antibody therapy against multiple myeloma and was approved in May 2016. Moreover, Janssen’s anti-CD38 antibody daratumumab reached its primary endpoint in the first Phase III… March 1, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Transgene approved for IV oncolytic virus trial …powerful antitumor immune response, and a full length anti-CTLA4 antibody. By selectively targeting tumor cells and expressing IL-12 and the anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected to… January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email